Anavex "Gottcha Moment"------" As such, we believe that the addition of the dihydrogen phosphate crystals to our platform could greatly benefit the patients at large.”---in other words---WGT !!!!!!
This is a great patent grant that will help shore up the hole there is in IP protection of A2-73 - yes there is a hole and you can read about it in the 10K reports and find Froll's posts on same.
However, that patent will require new trials with the new composition of matter before the patent has any practical utility. Not a bad thing either, especially as Anavex believes this new form of A2-73 has advantages over the current formulation.
Crystals plus patches...we are truly unique in this space!
“We believe the unique properties of the dihydrogen phosphate crystals make it possible in addition to convenient once daily oral dosing to also deliver the active (ANAVEX®2-73 freebase) in transdermal patches, which could simplify further the administration and boost patients’ compliance. As such, we believe that the addition of the dihydrogen phosphate crystals to our platform could greatly benefit the patients at large.”
This looks valuable, both because it can improve titration but also because by avoiding the digestive tract during dosing it probably improves the predictability of dose blood concentration levels, which appears to be the key efficacy variable. It will just raise the value of Anavex in the marketplace.
Market Data 
Markets 
AI
